ArticleEClinicalMedicine2024

Evaluation of all-cause mortality and cardiovascular safety in patients receiving chimeric antigen receptor T cell therapy: a prospective cohort study.

Felix Korell et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.